Axsome Therapeutics is showcasing Solriamfetol at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Solriamfetol for ADHD is the most APA-relevant Phase 3 program — FOCUS trial met its primary endpoint, and ADHD is a core psychiatric indication. BED is another psychiatry-managed condition. They'll position solriamfetol as a non-stimulant with a novel mechanism spanning multiple psychiatric conditions. Expect significant buzz if ADHD NDA filing timeline is announced.
Ask about: ADHD NDA filing timeline; FOCUS Phase 3 data details (effect size, tolerability vs. stimulants); BED ENGAGE trial enrollment/readout timeline; TAAR1 mechanism differentiation from standard stimulants; abuse liability profile. For psychiatrists, the non-stimulant ADHD angle with TAAR1 is compelling given stimulant concerns.
Multiple Phase 3 programs = ePRO+ as unified digital endpoint platform across ADHD, MDD-EDS, and BED. VoiceVitals measures attention/cognitive performance for ADHD and binge eating behavioral patterns — enriched digital endpoints beyond standard rating scales. QAview supports quality monitoring across their multi-trial portfolio.
Set up a follow-up with Axsome Therapeutics's team and Videra Health.
Email Ryan Roberts →